Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

BACKGROUND: We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF. METHODS: We identify all approved indications of immune checkpoint inhibitors based on RCTs between January 1, 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Fei, Zhang, Sheng, Wang, Qin, Li, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457752/
https://www.ncbi.nlm.nih.gov/pubmed/32867707
http://dx.doi.org/10.1186/s12885-020-07313-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457752/
https://www.ncbi.nlm.nih.gov/pubmed/32867707
http://dx.doi.org/10.1186/s12885-020-07313-2

Ejemplares similares